STELLARTECH COAGULATION SYSTEM, MODELS (1100C-115 & 1100C-230)
K032062 · Stellartech Research Corp. · GEI · Jul 29, 2003 · General, Plastic Surgery
Device Facts
| Record ID | K032062 |
| Device Name | STELLARTECH COAGULATION SYSTEM, MODELS (1100C-115 & 1100C-230) |
| Applicant | Stellartech Research Corp. |
| Product Code | GEI · General, Plastic Surgery |
| Decision Date | Jul 29, 2003 |
| Decision | SESE |
| Submission Type | Special |
| Regulation | 21 CFR 878.4400 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
The Stellartech Coagulation System is indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including but not limited to, the esophagus. Indications include Esophageal Ulcers, Mallory-Weiss tears, Arteriovenous Malformations, Angiomata, Barrett's Esophagus, Dieulafoy Lesions, and Angiodysplasia.
Device Story
Electrosurgical system for GI tract coagulation. Components: generator, probe connection module, probe, optional footswitch. Physician-operated in clinical setting. Generator delivers energy to probe to coagulate bleeding/non-bleeding tissue sites. Enables treatment of esophageal ulcers, tears, malformations, and lesions. Benefits patient by providing controlled hemostasis and tissue coagulation.
Clinical Evidence
No clinical data provided; substantial equivalence based on design and technological characteristics.
Technological Characteristics
Electrosurgical cutting and coagulation device (21 CFR 878.4400). System comprises a generator, probe connection module, and probe. Operates via electrosurgical energy delivery.
Indications for Use
Indicated for patients requiring coagulation of bleeding or non-bleeding gastrointestinal sites, including esophagus. Specific conditions: Esophageal Ulcers, Mallory-Weiss tears, Arteriovenous Malformations, Angiomata, Barrett's Esophagus, Dieulafoy Lesions, and Angiodysplasia.
Regulatory Classification
Identification
An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.
Predicate Devices
- Hobbs Medical Dilation Balloon Catheter (K834413)
- Stellartech Coagulation System (K013139)
- Stellartech Coagulation System (K023765)
Related Devices
- K032452 — MODIFICATION TO: STELLARTECH COAGULATION SYSTEM, MODELS 1100C-115 & 100C-230 · Stellartech Research Corp. · Aug 21, 2003
- K050831 — STELLARTECH COAGULATION SYSTEM 2, MODELS 1100C-115A AND 1100C-230A · Stellartech Research Corp. · Apr 12, 2005
- K032721 — MODIFICATION TO: STELLARTECH COAGULATION SYSTEM (MODELS 1100C-115 & 1100C-230) · Stellartech Research Corp. · Oct 6, 2003
- K013139 — STELLARTECH COAGULATION SYSTEM · Stellartech Research Corp. · Dec 18, 2001
- K062225 — HALO COAGULATION CATHETER · Barrx Medical, Incorporated · Aug 28, 2006
Submission Summary (Full Text)
{0}------------------------------------------------
K032062 1
# JUL 2 9 2003 510(k) Safety Summary
#### Name of Device A.
- Stellartech Coagulation System Trade Name: .
- Common Name: Electrosurgical Unit and Accessories .
- Classification Name: Device, Electrosurgical Cutting and Coagulation and Accessories . (21 CFR 878.4400)
## B. Predicate Devices
| Device | Premarket Notification |
|-----------------------------------------|------------------------|
| Hobbs Medical Dilation Balloon Catheter | K834413, 05/22/84 |
| Stellartech Coagulation System | K013139, 12/18/01 |
| Stellartech Coagulation System | K023765, 11/29/02 |
## C. Device Description:
The Stellartech Coagulation System consists of the following components.
- Stellartech Coagulation Generator ●
- Stellartech Coagulation Probe Connection Module ●
- Stellartech Coagulation Probe .
- Optional Stellartech Footswitch. .
The proximal end of the Stellartech Coagulation Probe connects to the Stellartech Coagulation Probe Connection Module. The proximal end of the Stellartech Coagulation Probe Connection Module cable connects to the Stellartech Coagulation Generator.
# D. Indicated Use
The Stellartech Coagulation System is indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including but not limited to, the esophagus. Indications include Esophageal Ulcers, Mallory-Weiss tears, Arteriovenous Malformations, Angiomata, Barrett's Esophagus, Dieulafoy Lesions, and Angiodysplasia.
## E. Technical characteristics
The technological characteristics of the Stellartech Coagulation System are substantially equivalent to those of the above listed predicate devices.
# F. Summary
By virtue of design, principles of operation, materials and intended use, the Stellartech Coagulation System is substantially equivalent to devices currently marketed in the United States.
{1}------------------------------------------------
Image /page/1/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo features a stylized eagle head facing left with three curved lines above it, representing feathers. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JUL 2 9 2003
Mr. Gary Seeger Vice President Quality Assurance and Regulatory Affairs Stellartech Research Corporation 1346 Bordeaux Drive Sunnyvale, California 94089
Re: K032062
Trade/Device Name: Stellartech Coagulation System Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical cutting and coagulation device and accessories Regulatory Class: II Product Code: GEI Dated: July 2, 2003 Received: July 8, 2003
Dear Mr. Seeger:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{2}------------------------------------------------
Page 2 - Mr. Gary Seeger
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Miriam C. Provost
(Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
510(k) NUMBER (IF KNOWN):
K032062
# DEVICE NAME:
Stellartech Coagulation System
INDICATIONS FOR USE:
The Stellartech Coagulation System is indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including but not limited to, the esophagus, Indications include Esophageal Ulcers, Mallory-Weiss tears, Arteriovenous Malformations, Angiomata, Barrett's Esophagus, Dieulafoy Lesions, and Angiodysplasia.
Miriam C. Provost
(Division of General, Restorative and Neurological Devices
OR
510(k) Number K032062
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109)
Over-The-Counter-Use